# Mytos

**Canonical:** https://apis.io/providers/mytos/  
**Website:** https://www.mytos.bio/  
**APIs profiled:** 0

Mytos is a contract development and manufacturing organization (CDMO) for regenerative medicine and cell therapy. Its iDEM automation platform automates every unit operation of cell culture — coating, seeding, feeding, imaging, passaging and harvesting — in standard 2D T-flask formats, letting clinical-stage biotech companies transfer their manual protocols to automated GMP production at up to 50% lower batch cost, with 10x less labor and cleanroom footprint per batch. Mytos operates a CDMO facility within the Cell and Gene Therapy Catapult site and is backed by Wing Venture Capital. No public developer/API surface was found during enrichment; the profile captures the company's verified security posture (trust center, SOC 2/SOC 3/21 CFR Part 11, domain security, vulnerability disclosure).

## Kin Score — 9.9 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 9.9).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 10.5 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 15.8 |
| Access Clarity | 15.8 |

Regulatory layer — **Health**: 21.3 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (3)

- **Mytos Domain Security** — TLSv1.3 · HSTS · DMARC
- **Mytos Vulnerability Disclosure** — contact published
- **Mytos Trust Center** — SOC 2 Type 2 (2025), SOC 3 (2025), 21 CFR Part 11

## Tags

Company, Biotechnology, Cell Therapy, Regenerative Medicine, Manufacturing Automation, CDMO, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/mytos/). Scores are computed from the provider's own public artifacts under a published rubric.